IRIS
CASTAGNA, ANTONELLA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 15.105
AS - Asia 14.435
NA - Nord America 10.585
SA - Sud America 3.668
AF - Africa 329
OC - Oceania 23
Continente sconosciuto - Info sul continente non disponibili 13
Totale 44.158
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 10.089
RU - Federazione Russa 8.873
SG - Singapore 5.173
CN - Cina 4.752
BR - Brasile 3.028
HK - Hong Kong 1.700
VN - Vietnam 1.470
SE - Svezia 1.445
IT - Italia 1.126
RO - Romania 778
FR - Francia 722
DE - Germania 721
GB - Regno Unito 392
IN - India 278
AR - Argentina 264
FI - Finlandia 255
CA - Canada 248
BD - Bangladesh 178
AT - Austria 171
MX - Messico 163
ID - Indonesia 135
PL - Polonia 135
IQ - Iraq 122
ZA - Sudafrica 117
NL - Olanda 105
EC - Ecuador 101
TR - Turchia 94
JP - Giappone 91
ES - Italia 85
CO - Colombia 77
IE - Irlanda 63
PK - Pakistan 59
UA - Ucraina 54
LT - Lituania 53
VE - Venezuela 53
MA - Marocco 48
PY - Paraguay 48
CL - Cile 44
SA - Arabia Saudita 43
PH - Filippine 39
UZ - Uzbekistan 39
EG - Egitto 37
TN - Tunisia 29
IR - Iran 26
AE - Emirati Arabi Uniti 25
MY - Malesia 24
NP - Nepal 22
BE - Belgio 21
IL - Israele 21
KE - Kenya 21
DZ - Algeria 20
UY - Uruguay 20
AU - Australia 18
DO - Repubblica Dominicana 18
PE - Perù 18
AZ - Azerbaigian 16
KZ - Kazakistan 15
MD - Moldavia 14
OM - Oman 14
AL - Albania 13
KR - Corea 13
JO - Giordania 12
SY - Repubblica araba siriana 12
EU - Europa 11
JM - Giamaica 11
BO - Bolivia 10
CH - Svizzera 10
CI - Costa d'Avorio 10
HN - Honduras 10
TH - Thailandia 10
CZ - Repubblica Ceca 8
ET - Etiopia 8
GT - Guatemala 8
NG - Nigeria 8
RS - Serbia 8
HR - Croazia 7
KW - Kuwait 7
LB - Libano 7
LU - Lussemburgo 7
PA - Panama 7
BB - Barbados 6
NI - Nicaragua 6
BH - Bahrain 5
GA - Gabon 5
NO - Norvegia 5
QA - Qatar 5
SI - Slovenia 5
SN - Senegal 5
SV - El Salvador 5
AM - Armenia 4
BG - Bulgaria 4
BW - Botswana 4
DK - Danimarca 4
GE - Georgia 4
GY - Guiana 4
HU - Ungheria 4
KH - Cambogia 4
PS - Palestinian Territory 4
PT - Portogallo 4
AO - Angola 3
Totale 44.097
Salva come PNG Salva come JPEG
Città #
Singapore 2.400
Dallas 2.235
Moscow 1.931
Hong Kong 1.688
San Jose 1.366
Ashburn 1.291
Shanghai 818
Hefei 685
Lauterbourg 589
Lawrence 542
Princeton 542
Ho Chi Minh City 513
New York 512
Beijing 498
Shenzhen 446
Milan 369
Hanoi 325
Los Angeles 280
São Paulo 279
Nuremberg 203
Munich 199
Helsinki 156
Orem 151
Boardman 126
Santa Clara 121
Warsaw 114
Denver 113
Rome 92
Rio de Janeiro 91
Montreal 87
Tokyo 84
Chennai 83
Da Nang 81
Guangzhou 81
London 78
Brooklyn 73
Council Bluffs 72
Johannesburg 72
Poplar 70
Haiphong 67
Vienna 67
Washington 67
Atlanta 65
Frankfurt am Main 65
Houston 62
Stockholm 61
Belo Horizonte 60
Curitiba 59
Amsterdam 58
Dublin 58
Turku 58
Mexico City 57
Toronto 57
Manchester 56
Brasília 54
Seattle 54
Chicago 53
Baghdad 52
Campinas 46
Phoenix 44
Porto Alegre 43
Biên Hòa 42
Quito 40
Cesano Boscone 39
Falkenstein 39
Lappeenranta 38
Tashkent 38
Pune 35
Ankara 34
Boston 33
Hải Dương 31
Guayaquil 30
The Dalles 30
Mumbai 29
Salvador 28
St Petersburg 28
Tianjin 28
Hangzhou 27
Columbus 26
Jakarta 26
Querétaro 26
Barnet 25
Istanbul 25
New Delhi 25
San Francisco 25
Thái Bình 25
Buenos Aires 24
Dhaka 24
Gatchina 24
Goiânia 24
Guarulhos 24
Sorocaba 23
Turin 23
Lahore 22
Brescia 21
Can Tho 21
Asunción 20
Bologna 20
Ribeirão Preto 20
Santiago 20
Totale 21.801
Salva come PNG Salva come JPEG
Nome #
The 118I reverse transcriptase mutation is the only independent genotypic predictor of virologic failure to a stavudine-containing salvage therapy in HIV-1-infected patients 1.359
Survival and predictors of death in people with HIV-associated lymphoma compared to those with a diagnosis of lymphoma in general population 469
What is the impact of SARS-CoV-2 pandemic on antimicrobial stewardship programs (ASPs)? The results of a survey among a regional network of infectious disease centres 269
The propensity for long-acting cabotegravir and rilpivirine every 2 months among HIV-infected people eligible for treatment 250
Monkeypox in a patient with undifferentiated connective tissue disease 250
Viral bloodstream detection in mpox patients: An observational multicentric study 233
Secondary infections in patients hospitalized with COVID-19: incidence and predictive factors 181
Viral clearance after early corticosteroid treatment in patients with moderate or severe covid-19 168
Fast reshaping of intensive care unit facilities in a large metropolitan hospital in Milan, Italy: facing the COVID-19 pandemic emergency 167
High Risk of Secondary Infections Following Thrombotic Complications in Patients With COVID-19 162
Gas-exchange deficit and systemic hypoperfusion in COVID-19 and non-COVID-19 young adult patients with pneumonia 154
Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS): Focus on the Pathophysiological and Diagnostic Role of Viruses 146
A follow-up study in asymptomatic HIV patients 146
Biobanking for COVID-19 research 144
48 week outcomes of maraviroc-containing regimens following the genotypic or Trofile assay in HIV-1 failing subjects: the OSCAR Study 143
Candidemia in COVID-19 patients: incidence and characteristics in a prospective cohort compared to historical non-COVID-19 controls 143
A comparision of brain biopsy and CSF-PCR in the diagnosis of CNS lesions in AIDS patients 142
Efficacy and safety of tocilizumab in severe COVID-19 patients: a single-centre retrospective cohort study 141
Impact of Levofloxacin for Prophylaxis of Pre-engraftment Bloodstream Infections after Allogeneic HSCT: A single-center Matched Analysis in an Endemic Country for Carbapenem-resistant Gram-negative Bacteria 141
Case Report: Favorable outcome of allogeneic hematopoietic stem cell transplantation in SARSCoV2 positive recipient, risk-benefit balance between infection and leukemia 139
The place of ceftazidime/avibactam and ceftolozane/tazobactam for therapy of haematological patients with febrile neutropenia 134
Levofloxacin prophylaxis vs no prophylaxis in neutropenic patients within an endemic country for carbapenem-resistant GNB 133
A case of breakthrough mpox infection in an individual non-responder to MVA-BN vaccination 131
Human Monkeypox Experience in a Tertiary Level Hospital in Milan, Italy, between May and October 2022: Epidemiological Features and Clinical Characteristics 130
Meningococcus B Vaccination Effectiveness Against Neisseria gonorrhoeae Infection in People Living With HIV: A Case-Control Study 128
Continuous positive airway pressure and pronation outside the Intensive Care Unit in COVID-19 acute respiratory distress syndrome 126
Characteristics of HIV pre-exposure prophylaxis users at first PrEP counselling visit: the CSL-PrEP cohort 126
Publisher Correction: Viral clearance after early corticosteroid treatment in patients with moderate or severe covid-19 (Scientific Reports, (2020), 10, 1, (21291), 10.1038/s41598-020-78039-1) 125
Mpox Outbreak 2022: A Comparative Analysis of the Characteristics of Individuals Receiving MVA-BN Vaccination and People Diagnosed with Mpox Infection in Milan, Italy 124
Allogeneic bone marrow transplantation in HIV people with hematological malignancies: Post-transplant cyclophosphamide to overcome the HLA-matching barrier 123
Risk of mortality in people with chronic liver diseases hospitalized for Coronavirus disease of 2019 (COVID-19) in a tertiary hospital in Lombardy, Italy 121
HIV viral load monitoring during monkeypox virus infection among people with HIV 118
Cardiac implantable electronic device infections: impact of initiation of antimicrobial treatment before or after device removal on microbiological yield 117
Trends of Antimicrobial Susceptibility of Neisseria gonorrhoeae Isolates between 2012 and 2023: Results from an Open Italian Cohort 116
Outcome of Darunavir–Cobicistat-Based Regimens in HIV-Infected People Who Have Experienced Virological Failure 116
High-Risk Neutropenic Fever and Invasive Fungal Diseases in Patients with Hematological Malignancies 116
Antibiotic appropriateness for Gram-negative bloodstream infections: impact of infectious disease consultation 116
Impact of Remdesivir on SARS-CoV-2 Clearance in a Real-Life Setting: A Matched-Cohort Study 116
Epicardial adipose tissue characteristics, obesity and clinical outcomes in COVID-19: A post-hoc analysis of a prospective cohort study 116
Analysis of the faecal microbiome during analytical treatment interruption in people with chronic HIV infection and long-lasting virological suppression (APACHE study) 114
COVID-19 survival associates with the immunoglobulin response to the SARS-CoV-2 spike Receptor Binding Domain 114
Associations of statins and antiretroviral drugs with the onset of type 2 diabetes among HIV-1-infected patients 111
Analytical treatment interruption in chronic HIV-1 infection: Time and magnitude of viral rebound in adults with 10 years of undetectable viral load and low HIV-DNA (APACHE study) 111
Circulating cathodic antigen (CCA) urine rapid test for diagnosis of Schistosoma mansoni infestation: preliminary data of a cohort study of Egyptian patients coming from an endemic area 111
A whole-genome association study of major determinants for host control of HIV-1 110
Risk of Cardiovascular Diseases or Mortality in People with Higher Values of HIV-1 DNA 109
Breakthrough monkeypox infection among individuals previously immunized with smallpox or monkeypox vaccination 109
Early predictors of clinical outcomes of COVID-19 outbreak in Milan, Italy 109
Coronavirus Disease 2019 in Recipient of Allogeneic Hematopoietic Stem Cell Transplantation: Life-threating Features Within the Early Post-engraftment Phase 109
Subclinical myocardial dysfunction in patients recovered from COVID-19 109
Treatment success of rescue regimens after dual therapy failure in people living with HIV in a real-life setting 109
Factors Associated with Low-Level Viremia in People Living with HIV in the Italian Antiviral Response Cohort Analysis Cohort: A Case-Control Study 108
Association of high-risk sexual behaviours with sexually transmitted infections among men who have sex with men living with HIV 108
Achieving virological control in pan-resistant HIV-1 infection: A case series 108
Post-neurosurgical Nocardia meningoventriculitis: a case report and review of the literature 108
Access and response to direct antiviral agents (DAA) in HIV-HCV co-infected patients in Italy: Data from the Icona cohort 108
High Propensity to Switch to Long-acting Injectable HIV PrEP with Cabotegravir in a Cohort of Oral PrEP Experienced Men who Have Sex with Men in Italy 106
Coadministration of isavuconazole and sirolimus in allogeneic hematopoietic stem cell transplant recipients 105
Implementation of recombinant anti-herpes zoster vaccination in people living with HIV: a single-center experience 105
Safety of rezafungin as a long-term treatment option in two patients with complicated fungal infections: two cases from Lecco Hospital (Italy) 105
Testosterone in males with COVID-19: A twelve-month cohort study 105
Exploring the Association between Delirium and Malnutrition in COVID-19 Survivors: A Geriatric Perspective 105
Dynamics of HIV-1 POL antibodies after ART in chronic HIV-1 infection 105
Serum IgG1 and IgG4 could contribute to partial control of viral rebound in chronically HIV-1-infected patients 105
Profiling Covid-19 patients with respect to level of severity: an integrated statistical approach 104
Abacavir usage patterns and hypersensitivity reactions in the EuroSIDA cohort 104
T and B cell responses to cytomegalovirus antigens in healthy blood donors and bone marrow transplant recipients 104
Changes in homeostatic model assessment for insulin resistance (HOMA-IR) index in treated HIV-1 infected people on virological suppression who switched to a different antiretroviral regimen 104
Beyond stigma: Monkeypox infection in a 27-year-old woman 103
Factors Associated with Health Care Providers' Preference for Forgoing an Oral Lead-In Phase When Initiating Long-Acting Injectable Cabotegravir and Rilpivirine in the SOLAR Clinical Trial 103
High-dose anakinra in addition to standard of care including corticosteroids in patients with severe COVID-19 treated with non-invasive ventilation 103
Brief Report: Association Between Low HIV-1 DNA and Western Blot Reactivity to HIV-1 Pol in Chronically Infected Individuals 103
Viral Hepatitis and Human Papillomavirus Vaccination during HIV Pre-Exposure Prophylaxis: Factors Associated with Missed Vaccination 102
Non-O1 and non-O139 Vibrio cholerae Septicemia and Cellulitis: a Case Report 102
Combined plasma levels of IL-10 and testosterone, but not soluble HLA-G5, predict the risk of death in COVID-19 patients 102
Monkeypox infection in a hemopoietic stem cell and heart transplant recipient 102
SARS-CoV-2 IgG/IgM Rapid Test as a Diagnostic Tool in Hospitalized Patients and Healthcare Workers, at a large Teaching Hospital in northern Italy, during the 2020 COVID-19 Pandemic 102
Probable West Nile Virus hepatitis: Case report 101
Alterations in glutamate, arginine, and energy metabolism characterize cerebrospinal fluid and plasma metabolome of persons with HIV-associated dementia 101
Sexually transmitted infections in men who have sex with men with tenofovir/emtricitabine- or cabotegravir-resistant HIV 101
Monkeypox infection among men who have sex with men: PCR testing on seminal fluids 100
Antiretroviral therapy in geriatric HIV patients: The GEPPO cohort study 100
Bictegravir 100
Inflammation and microbial translocation measured prior to combination antiretroviral therapy (cART) and long-term probability of clinical progression in people living with HIV 100
Failure of on-demand pre-exposure prophylaxis: the risk of HIV drug resistance 100
Isolated monkeypox proctitis among men who have sex with men 99
Persistent ocular mpox infection in an immunocompetent individual 99
Ability of different lopinavir genotypic inhibitory quotients to predict 48-week virological response in highly treatment-experienced HIV-infected patients receiving lopinavir/ritonavir 99
A RELATIVELY SLOW RISK OF DISEASE PROGRESSION IN HIV-POSITIVE PATIENTS WITH INDOLENT INFECTION HAS BEEN FOUND IN THE ICONA COHORT 99
Respiratory Impairment Predicts Response to IL-1 and IL-6 Blockade in COVID-19 Patients With Severe Pneumonia and Hyper-Inflammation 99
Long-term outcome in a person with pandrug-resistant HIV: the added value of a multidisciplinary approach 98
A four-drug combination oral tablet of darunavir, cobicistat, emtricitabine, and tenofovir alafenamide for the treatment of HIV-1 infection in adults 98
Tick-borne encephalitis seroprevalence in northern Italy: a cross-sectional study on a randomly selected population 97
A nucleoside-sparing regimen of dolutegravir plus ritonavir-boosted atazanavir in HIV-1-infected patients with virological failure: the DOLATAV study 97
Impact of predicted HLA class I immunopeptidome on viral reservoir in a cohort of people living with HIV in Italy 97
Clinico-Virological Outcomes and Mutational Profile of SARS-CoV-2 in Adults Treated with Ribavirin Aerosol for COVID-19 Pneumonia 96
One Year of Long-Acting Cabotegravir and Rilpivirine in People With Human Immunodeficiency Virus and Long Exposure to Antiretroviral Therapy: Data From the SCohoLART Study 96
Efficacy, safety, and tolerability of switching to long-acting cabotegravir plus rilpivirine versus continuing fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed adults with HIV, 12-month results (SOLAR): a randomised, open-label, phase 3b, non-inferiority trial 96
Atazanavir/ritonavir monotherapy: 96 week efficacy, safety and bone mineral density from the MODAt randomized trial 96
Response to combination antiretroviral therapy: Variation by age 95
Totale 13.587
Salva come PNG Salva come JPEG
Categoria #
all - tutte 268.868
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 268.868
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202111 0 0 0 0 0 0 0 0 0 0 7 4
2021/2022417 1 0 0 137 26 29 36 64 36 29 16 43
2022/20232.835 1.206 552 220 27 36 257 175 185 99 19 35 24
2023/20242.162 45 66 641 171 178 410 59 180 8 45 113 246
2024/20259.554 1.078 150 178 281 363 852 2.013 777 1.368 1.050 587 857
2025/202629.655 2.115 2.342 2.648 4.230 2.273 989 2.700 2.187 7.675 1.818 678 0
Totale 45.288